Bromocriptine and premenstrual tension : a clinical and hormonal study

Thirty-four patients suffering from the premenstrual syndrome were studied during 5 consecutive menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random, double-blind manner, each patient serving as her own control. Bromocriptine...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1982), 2 vom: 11., Seite 107-13
1. Verfasser: Andersch, B (VerfasserIn)
Weitere Verfasser: Hahn, L
Format: Aufsatz
Sprache:English
Veröffentlicht: 1982
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Journal Article Randomized Controlled Trial Bromocriptine 3A64E3G5ZO Progesterone 4G7DS2Q64Y Prolactin 9002-62-4
LEADER 01000caa a22002652c 4500
001 NLM071783202
003 DE-627
005 20250129015039.0
007 tu
008 231222s1982 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0240.xml 
035 |a (DE-627)NLM071783202 
035 |a (NLM)7201645 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Andersch, B  |e verfasserin  |4 aut 
245 1 0 |a Bromocriptine and premenstrual tension  |b a clinical and hormonal study 
264 1 |c 1982 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 17.09.1982 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Thirty-four patients suffering from the premenstrual syndrome were studied during 5 consecutive menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random, double-blind manner, each patient serving as her own control. Bromocriptine (1.25 mg twice daily) was given for 3 cycles and placebo for 1 cycle. Serum prolactin levels were within normal limits without treatment and were significantly reduced by bromocriptine. Serum progesterone did not change during treatment. Medication considerably improved all the premenstrual symptoms but bromocriptine was not significantly better than placebo. These results do not support the hypothesis that prolactin alone causes premenstrual symptoms 
650 4 |a Clinical Trial 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Bromocriptine  |2 NLM 
650 7 |a 3A64E3G5ZO  |2 NLM 
650 7 |a Progesterone  |2 NLM 
650 7 |a 4G7DS2Q64Y  |2 NLM 
650 7 |a Prolactin  |2 NLM 
650 7 |a 9002-62-4  |2 NLM 
700 1 |a Hahn, L  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)  |d 1995  |g 3(1982), 2 vom: 11., Seite 107-13  |w (DE-627)NLM023961570 
773 1 8 |g volume:3  |g year:1982  |g number:2  |g day:11  |g pages:107-13 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_121 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 3  |j 1982  |e 2  |b 11  |h 107-13